Broad-spectrum chemokine inhibitor

Early peptides

The observation that the chemokine CCL2 is potentially responsible for the recruitment of macrophages to atherosclerotic lesions initiated a campaign of research into the a class of molecules that would inhibit the trafficking of leukocytes and act as a new generation of anti-inflammatory agents. ‘Peptide 3’, a dodecapeptide section of CCL2, designed as an allosteric inhibitor of MCP-1 induced leukocyte chemotaxis, was quickly shown by leukocyte migration assay to be a functional inhibitor of many chemokines in vitro with similar potency. The potency of this peptide could be increased by cyclisation and the use of the reverse sequence of D-amino acids. This peptide is called NR58-3.14.3.

In vivo anti-inflammatory activity

The cyclic peptide NR58-3.14.3 was shown to be a powerful anti-inflammatory agent in vivo, inhibiting inflammation in a number of disease models such as atherosclerosis, ischemia, lung disease, surgical adhesions, endometriosis and pulmonary graft-versus-host disease. It has been suggested that blockage of chemokine function using these molecules should not have a detrimental toxicological effect.

Anti-HIV activity

Cyclic peptide NR58-3.14.3 has also been shown to inhibit HIV replication.

Preterm Labor

The BSCI compound called 'BN83470' in pregnant mice averted infection-induced preterm birth (PTB) by blocking various inflammatory pathways in the uterus and preventing the infiltration of immune cells into the uterine myometrium. In a nonhuman primate model of Group B Streptococcus (GBS)-induced preterm labour, another BSCI compound called 'FX125L' was able to inhibit preterm labour and suppress the cytokine response. No antibiotics were administered during these experiments, allowing the GBS infection to progress and invade the amniotic cavity and the fetus. Despite the invasive GBS infection, prophylactic BSCI treatment significantly reduced the levels of cytokines in the amniotic fluid, fetal plasma, lung, and brain, indicating its ability to suppress the inflammatory response. Current animal studies have not shown any significant fetal toxicity associated with BSCI compounds. However, further research, particularly through human pre-clinical trials, is now underway to understand the impact of BSCIs on the fetal immune response and development.

Small molecule drug candidates

The key amino acids of the BSCI peptides required for activity have been identified, and the tripeptide AcNH-Trp-Val-Gln-OH was shown to itself be a BSCI in the low micromolar range. Based on this structure a number of peptide mimetics were designed, including a range of 3-acylaminoglutarimides, with low nanomolar BSCI potencies. The search for increased stability and potency led to the development of 3-acylaminolactams, with picomolar potencies in vitro and high anti-inflammatory activity in vivo. A small molecule member of this class of BSCIs called FX125L, under development by Funxional Therapeutics, has recently completed phase 2 clinical trials.

References

References

1. (2005). "Broad Spectrum Chemokine Inhibitors Related to NR58-3.14.3". Mini-Rev. Med. Chem..
2. (1999). "Monocyte Chemoattractant Protein-1 but Not Tumor Necrosis Factor-{alpha} Is Correlated With Monocyte Infiltration in Mouse Lipid Lesions". Circulation.
3. (2004). "Tools for anti-inflammatory drug design: In vitro models of leukocyte migration". Med. Res. Rev..
4. (1999). "Identification of oligopeptide sequences which inhibit migration induced by a wide range of chemokines". Biochem. J..
5. (2001). "The pan-chemokine inhibitor NR58-3.14.3 abolishes tumour necrosis factor-alpha accumulation and leucocyte recruitment induced by lipopolysaccharide in vivo". Immunology.
6. (2000). "Quantitative analysis of a synthetic peptide, NR58-3.14.3, in serum by LC-MS with inclusion of a diastereomer as internal standard". Anal. Biochem..
7. (2003). "Broad-spectrum chemokine inhibitors (BSCIs) and their anti-inflammatory effects in vivo". Biochem. Pharmacol..
8. (2005). "Broad-spectrum chemokine inhibition reduces vascular macrophage accumulation and collagenolysis consistent with plaque stabilization in mice". J. Vasc. Res..
9. (2001). "Neuroprotection in ischemia-reperfusion injury: an antiinflammatory approach using a novel broad-spectrum chemokine inhibitor". J. Cereb. Blood Flow Metab..
10. (2004). "Novel broad-spectrum chemokine inhibitor protects against lung ischemia-reperfusion injury". J. Heart Lung Transplant..
11. (2007). "The MHP36 line of murine neural stem cells expresses functional CXCR1 chemokine receptors that initiate chemotaxis in vitro". J. Neuroimmunol..
12. (2003). "Broad-spectrum chemokine inhibition ameliorates experimental obliterative bronchiolitis". Ann. Thorac. Surg..
13. (2005). "Inhibition of chemokines prevents intraperitoneal adhesions in mice". Hum. Reprod..
14. (2007). "The Broad-Spectrum Chemokine Inhibitor NR58-3.14.3 Suppresses the Implantation and Survival of Human Endometrial Implants in the Nude Mice Endometriosis Model". Reprod. Sci..
15. (2009). "Preventive usage of broad spectrum chemokine inhibitor NR58-3.14.3 reduces the severity of pulmonary and hepatic graft-versus-host disease". Int. J. Hematol..
16. (2005). "The Toxicology of Chemokine Inhibition". Mini Rev. Med. Chem..
17. (2005). "Blockade of chemokine-induced signalling inhibits CCR5-dependent HIV infection in vitro without blocking gp120/CCR5 interaction". Retrovirology Med. Chem..
18. (September 2014). "Inhibition of infection‐mediated preterm birth by administration of broad spectrum chemokine inhibitor in mice". Journal of Cellular and Molecular Medicine.
19. (2020). "A Broad Spectrum Chemokine Inhibitor Prevents Preterm Labor but Not Microbial Invasion of the Amniotic Cavity or Neonatal Morbidity in a Non-human Primate Model". Frontiers in Immunology.
20. (January 2022). "A Broad-Spectrum Chemokine Inhibitor Blocks Inflammation-Induced Myometrial Myocyte–Macrophage Crosstalk and Myometrial Contraction". Cells.
21. (2021-10-15). "Decidual Inflammation Drives Chemokine-Mediated Immune Infiltration Contributing to Term Labor". The Journal of Immunology.
22. (2021-06-29). "Landscape of Preterm Birth Therapeutics and a Path Forward". Journal of Clinical Medicine.
23. (2002). "Design, Synthesis, and Preliminary Pharmacological Evaluation of N-Acyl-3-aminoglutarimides as Broad-Spectrum Chemokine Inhibitors in Vitro and Anti-inflammatory Agents in Vivo". J. Med. Chem..
24. (2005). "Identification of 3-(Acylamino)azepan-2-ones as Stable Broad-Spectrum Chemokine Inhibitors Resistant to Metabolism in Vivo". J. Med. Chem..
25. (2009). "Highly Potent, Orally Available Anti-inflammatory Broad-Spectrum Chemokine Inhibitors". J. Med. Chem..